On the other hand, certain interventions can be used clinically to reduce Ca+2, PO-4, GAL-3 and increase the content of Klotho, thereby reducing the risk of cardiovascular diseases in patients with CKD. The gene discussed is LGALS3; the disease is chronic kidney disease.